Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases
Clinical Trials: Idiopathic Pulmonary Fibrosis
A listing of clinical trials currently looking for volunteers to enroll in Idiopathic Pulmonary Fibrosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Birmingham :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Jasper : 1199.33.01012 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Arizona
Phoenix : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Phoenix : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Scottsdale : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Tucson : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Tuscon : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Phoenix : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Phoenix : 1199.33.01003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Phoenix : Arizona Pulmonary Specialists
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Scottsdale :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Tucson : University of Arizona
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
California
LaJolla : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Los Angeles : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Los Angeles : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Sacramento : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
San Diego : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
San Diego : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
San Francisco : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
San Francisco : University California-San Francisco
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
San Jose : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Stanford : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Stanford : Stanford University Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Torrance : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Los Angeles : VA Greater LA Health Care System-UCLA
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Los Angeles : David Geffen School of Medicine, UCLA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Sacramento : University of California- Davis Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
San Francisco : Investigational Site Number 840008
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Torrance : 1199.33.01007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Colorado
Denver : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Wheat Ridge : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Connecticut
New Haven : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Danbury : 1199.33.01006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New Haven :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Stamford : 1199.33.01017 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Florida
Brandon : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Clearwater : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Gainesville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Gainesville : University of Florida/Pulmonary, Critical Care & Sleep Medicine
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Jacksonville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Miami : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Miami : University of Miami
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Orlando : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Sarasota : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
St. Petersburg : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Jacksonville : Investigational Site Number 840009
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Jacksonville : Investigational Site Number 840011
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Orlando :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Tampa : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Tampa :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Georgia
Altanta : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Altanta : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Austell : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Duluth : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Decatur :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Idaho
Coeur d'Alene : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Illinois
Chicago : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Chicago : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Chicago : University of Chicago
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Elk Grove Village : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Evanston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Maywood : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Peoria : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Joliet : Investigational Site Number 840004
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Maywood : Investigational Site Number 840005
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Indiana
Muncie : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Iowa
Iowa City : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Kansas
Kansas City : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Olathe : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Wichita : Wichita Clinic, PA
A Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)
Wichita : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Wichita : 1199.33.01023 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Wichita :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Wichita : Investigational Site Number 840002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Kentucky
Lexington : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Louisville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Louisville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Louisville :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Louisville : Kentuckiana Pulmonary Associates
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Louisiana
New Orleans : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Maine
Portland : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Maryland
Baltimore : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Massachusetts
Boston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Boston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Boston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Boston : Beth Israel Deaconess Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Boston : Brigham and Women's Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Boston : Massachusetts General Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Springfield : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Michigan
Ann Arbor : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Detroit : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Minnesota
Minneapolis : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Rochester : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Minneapolis : 1199.33.01005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Minneapolis : Investigational Site Number 840003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Missouri
Chesterfield : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Kansas City : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
St. Louis : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Chesterfield :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
St. Louis : Washington University School of Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Nebraska
Omaha : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Omaha : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Nevada
Reno : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
New Hampshire
Lebanon : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lebanon : Dartmouth-Hitchcock Medical Center Pulmonary Dept.
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
New Jersey
Newark : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Summit : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
New Brunswick :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Newark : University of Medicine and Dentistry of New Jersey
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Summit : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
New York
Jamaica : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Mineola : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Mineola : Winthrop University Hospital Clinical Trials Center
Idiopathic Pulmonary Fibrosis
New York : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
New York : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
New York : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Rochester : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Albany : 1199.33.01041 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Jamaica : 1199.33.01010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New York :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
North Carolina
Asheville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Durham : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Greensboro : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Durham : Novartis Investigative Site
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Ohio
Cincinnati : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Cincinnati : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Cleveland : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Cleveland : Cleveland Clinic
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Columbus : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Toledo : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cleveland : Cleveland Clinic
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Columbus :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Columbus : Ohio State University, Martha Morehouse Medical Plaza
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Oklahoma
Oklahoma City : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Tulsa : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Oregon
Portland : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Tualatin : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Portland : 1199.33.01004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Pennsylvania
Danville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Ephrata : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Philadelphia : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Philadelphia : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Pittsburgh : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Pittsburgh : University of Pittsburgh Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Pittsburgh : Allegheny General Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
South Carolina
Charleston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Charleston : 1199.33.01024 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Tennessee
Nashville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Nashville : Vanderbilt University Medical Center
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
View More »
Nashville :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Shelbyville : 1199.33.01016 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Texas
Dallas : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Dallas : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Houston : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Houston : Baylor College of Medicine and The Methodist Hospital
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
San Antonio : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Dallas :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Longview : 1199.33.01019 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
McKinney : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
McKinney : 1199.33.01021 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
San Antonio : 1199.33.01001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Utah
Salt Lake City : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Salt Lake City :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Salt Lake City : University of Utah
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Vermont
Colchester : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Colchester :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Virginia
Charlottesville : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Falls Church : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Richmond : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Falls Church :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Washington
Tacoma : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Wisconsin
Madison : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Milwaukee : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Madison :
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Milwaukee : Aurora St. Luke's Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Australia
Adelaide : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Bedford Park : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Box Hill : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Camperdown : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Chermside : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Concord : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Darlinghurst : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Nedlands : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Perth : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Prahran : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
South Brisbane : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Woodville South : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Camperdown : 1199.33.61001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Concord : 1199.33.61002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Frankston : 1199.33.61005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Melbourne : 1199.33.61004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Belgium
Bruxelles : 1199.33.32004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leuven : 1199.33.32001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leuven : Investigational Site Number 056001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Yvoir : 1199.33.32002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Brazil
Belo Horizonte : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Porto Alegre : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Porto Alegre : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Rio de Janeiro : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Santo André : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
São Paulo : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
São Paulo : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Canada
Halifax : 1199.33.02003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Vancouver : Investigational Site Number 124002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Windsor : Research Site
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Chile
Santiago : Investigational Site Number 152001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Santiago : Investigational Site Number 152002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
China
Beijing : Peking Union Medical College Hospital
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
Czech Republic
Prague 4 : 1199.33.42003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Prague 8 : 1199.33.42002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Usti nad Labem : 1199.33.42001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Finland
Vantaa : 1199.33.35802 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
France
BOBIGNY Cedex : 1199.33.33002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lille Cedex : 1199.33.33009 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Lyon cedex : 1199.33.33011 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Marseille : 1199.33.33013 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Montpellier Cedex 5 : 1199.33.33008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Nice Cedex 1 : 1199.33.33003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Paris : 1199.33.33006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Paris Cedex 18 : 1199.33.33001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Reims Cedex : 1199.33.33007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Rennes Cedex 9 : 1199.33.33004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Toulouse Cedex 9 : 1199.33.33012 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Germany
Bamberg : 1199.33.49008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Bochum : Klinik III für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufs¬genossen-schaftliches Universitätsklinikum Bergmannsheil GmbH
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Coswig : 1199.33.49010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Donaustauf : 1199.33.49005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Essen : 1199.33.49001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Freiburg/Breisgau : 1199.33.49002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Großhansdorf : 1199.33.49003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Hannover : Klinik für Pneumologie, Medizinische Hochschule Hannover
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Heidelberg : 1199.33.49007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Heidelberg : Pneumologie und Beatmungsmedizin, Thoraxklinik,Universitätsklinikum
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Immenhausen : 1199.33.49013 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Leipzig : Abteilung für Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universitätsklinikum Leipzig AöR
Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)
Mainz : 1199.33.49004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Greece
Athens : 1199.33.30005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Heraklion : 1199.33.30001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Italy
Forli' : 1199.33.39008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Modena : 1199.33.39001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Napoli : 1199.33.39011 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Pisa : 1199.33.39006A Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Roma : 1199.33.39010 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Korea, Republic of
Bucheon : 1199.33.82002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Incheon : 1199.33.82004 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82007 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Seoul : 1199.33.82001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
View More »
Seoul : 1199.33.82003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Mexico
Chihuahua : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Guadalajara : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Hermosillo : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Mexico : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
MONTERREY : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Monterrey : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Zapopan : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
View More »
Mexico City : Investigational Site Number 484003
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Monterrey : Investigational Site Number 484002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Netherlands
Nieuwegein : 1199.33.31001 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
New Zealand
Auckland : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Christchurch : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Peru
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Lima : Research Site
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ASCEND)
Portugal
Lisboa : 1199.33.35102 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Porto : 1199.33.35101 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Spain
Barcelona : Investigational Site Number 724001
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
Barcelona : Investigational Site Number 724002
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
L´Hospitalet de Llobregat : 1199.33.34005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Sevilla : 1199.33.34008 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
United Kingdom
Aberdeen : 1199.33.44006 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Birmingham : 1199.33.44003 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Birmingham : 1199.33.44005 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
London : 1199.33.44002 Boehringer Ingelheim Investigational Site
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
London : Royal Brompton Hospital
IPF Drug Deposition Study
View More »
London : Royal Brompton Hospital
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Nottingham : Nottingham University Hospitals NHS Trust
Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)
